Table 1.

Health Canada-approved novel therapies for HER2-positive metastatic breast cancer.

Drug	Route	Frequency	Combination	OS Benefit
Pertuzumab	IV	q3wk	Trastuzumab + taxane	15.7 months [7,8]
T-DM1	IV	q3wk	None	6.8 months [9,10]
Tucatinib	PO	Daily	Trastuzumab + capecitabine	4.5 months [11]
T-DXd	IV	q3wk	None	Likely, but awaiting further analysis [12,13]
Lapatinib	PO	Daily	Capecitabine	None [14]
Neratinib	PO	Daily	Capecitabine	None [15]